2022
DOI: 10.1111/ejh.13853
|View full text |Cite
|
Sign up to set email alerts
|

Activated prothrombin complex concentrate to treat bleeding events in acquired hemophilia A: BAHAS study

Abstract: Objective: Activated prothrombin complex concentrate (aPCC) is a bypassing agent indicated to treat bleeds in patients with acquired hemophilia A (AHA). Nevertheless, its efficacy and safety in the real-world setting have not often been addressed. Methods:We report the experience of Spanish reference centers for coagulation disorders and from acquired hemophilia Spanish Registry (AHASR) from August 2012 to February 2021. Follow-up period of 30 days after aPCC withdrawal.Results: Thirty patients with a median a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 23 publications
0
1
0
Order By: Relevance
“…R time is the latency until clot formation begins with 2 mm amplitude, K time is the time from R until the clot reaches 20 mm, alpha angle shows the rate at which fibrin cross linking occurs, MA (maximum amplitude) shows the highest point on the TEG curve indicating maximum clot strength, and LY30 shows fibrinolytic activity 30 minutes after MA [9,10]. aPCC was subsequently administered which, of note, has been recommended to use as a bypassing agent in AHA patients [9]. In a time-sensitive scenario, TEG may guide tailored management as mixing studies take 3-4 hours to conclude and result.…”
Section: Discussionmentioning
confidence: 99%
“…R time is the latency until clot formation begins with 2 mm amplitude, K time is the time from R until the clot reaches 20 mm, alpha angle shows the rate at which fibrin cross linking occurs, MA (maximum amplitude) shows the highest point on the TEG curve indicating maximum clot strength, and LY30 shows fibrinolytic activity 30 minutes after MA [9,10]. aPCC was subsequently administered which, of note, has been recommended to use as a bypassing agent in AHA patients [9]. In a time-sensitive scenario, TEG may guide tailored management as mixing studies take 3-4 hours to conclude and result.…”
Section: Discussionmentioning
confidence: 99%
“…As suggested, in the initial treatment with rFVIIa, bolus injections of 90 μg/kg every 2–3 h should be used until hemostasis is achieved [ 33 ]. In the study of Mingot-Castellano et al, aPCCs as first-line treatment ended the bleeding in 13 out of 14 (92.9%) AHA patients, while as a second-line treatment, it stopped the bleeding in all the patients reported [ 89 ]. aPCCs are also used as a prophylactic agent for bleeding events in patients with acquired hemophilia and inhibitors [ 90 ].…”
Section: Treatment Approaches In Ahamentioning
confidence: 99%